MicroRNA 382 (MIR382)

MicroRNA 382 (MIR382) is a small, non-coding RNA from the microRNA family, approximately 20–24 nucleotides in length, involved in post-transcriptional regulation of gene expression in humans[2]. MIR382 is transcribed as part of a primary transcript, processed by Drosha and Dicer enzymes, and incorporated into the RNA-induced silencing complex (RISC). It regulates cellular processes including proliferation, migration, cell cycle, apoptosis, angiogenesis, and chemotherapy resistance by binding to and downregulating specific mRNA targets such as KLF12, HIPK3, PTEN, and SLC7A11[1][3][4]. MIR382 can act as either a tumor suppressor or oncogene depending on cellular context: it suppresses tumor growth and enhances chemosensitivity in colorectal cancer, promotes angiogenesis in gastric cancer, and modulates drug resistance and cell survival in a range of malignancies[1][3][4]. Altered expression of MIR382 is also observed in autoimmune, psychiatric, and viral diseases, making it a potential biomarker and therapeutic target for diverse human conditions[1][2].

Other names

hsa-mir-382mir-382MIRN382MIR382

Regulates gene expression by targeting 3′ untranslated regions of mRNAs, leading to mRNA degradation or translation inhibition[2][3][4]. Alters cellular signaling pathways (e.g., PI3K/AKT/mTOR, via regulation of PTEN; affects KLF12 and HIPK3 expression)[1][3][4].